New hope for lung cancer patients with lung scarring: trial tests safer treatments
NCT ID NCT07420439
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This study is for people with advanced non-small cell lung cancer who also have interstitial lung disease (ILD), a condition that causes lung scarring. Many doctors avoid treating these patients due to risks of worsening ILD. The trial will test a specific chemotherapy as first treatment and an immunotherapy drug as second treatment to see if they are safe and effective. About 108 participants will be enrolled to gather much-needed data for this group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE (ILD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Angers - CHU
Angers, France
Contact Email: •••••@•••••
-
Annecy - CH
Pringy, France
Contact Email: •••••@•••••
-
Besançon - CHU
Besançon, France
Contact Email: •••••@•••••
-
Bobigny - APHP - Hôpital Avicenne
Bobigny, France
Contact Email: •••••@•••••
-
Bordeaux - CHU
Pessac, France
Contact Email: •••••@•••••
-
Boulogne - APHP Ambroise Paré
Boulogne-Billancourt, France
Contact Email: •••••@•••••
-
Boulogne-Sur-Mer - CH
Boulogne-sur-Mer, France
Contact Email: •••••@•••••
-
Brest - CHU
Brest, France
-
Caen - CHU Côte de Nacre
Caen, 14000, France
-
Clermont-Ferrand - CHU
Clermont-Ferrand, France
Contact Email: •••••@•••••
-
Colmar - CH
Colmar, 68000, France
-
Créteil - CHI
Créteil, France
Contact Email: •••••@•••••
-
Dijon - CHU Bocage
Dijon, France
Contact Email: •••••@•••••
-
Grenoble - CHU
Grenoble, 38000, France
-
Lille - CHU
Lille, France
Contact Email: •••••@•••••
-
Lyon - HCL
Lyon, France
Contact Email: •••••@•••••
-
Marseille - AP-HM Hôpital Nord
Marseille, France
Contact Email: •••••@•••••
-
Marseille - Institut Paoli Calmette
Marseille, France
Contact Email: •••••@•••••
-
Metz - Hôpital Robert Schuman
Metz, France
Contact Email: •••••@•••••
-
Montpellier - CHU
Montpellier, France
Contact Email: •••••@•••••
-
Nantes - CHU Hôpital Laënnec
Nantes, France
Contact Email: •••••@•••••
-
Paris - APHP - Tenon
Paris, 75020, France
Contact Email: •••••@•••••
-
Paris - APHP Bichat
Paris, France
Contact Email: •••••@•••••
-
Paris - APHP Cochin
Paris, France
Contact Email: •••••@•••••
-
Paris - APHP Pitié-salpêtrière
Paris, France
Contact Email: •••••@•••••
-
Paris - Saint Joseph
Paris, France
Contact Email: •••••@•••••
-
Rennes - CHU
Rennes, France
Contact Email: •••••@•••••
-
Strasbourg - NHC
Strasbourg, 63000, France
Contact Email: •••••@•••••
-
Suresnes - Foch
Suresnes, France
Contact Email: •••••@•••••
-
Tours - CHU
Tours, France
Contact Email: •••••@•••••
-
Villefranche-Sur-Saône - Hôpital Nord-Ouest
Villefranche-sur-Saône, France
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple-drug cocktail re-sensitize lung cancer to treatment?
- Which finger or earlobe? a study tests the best spot for oxygen monitoring in lung disease
- Can an inhaled powder stop lung scarring? a safety trial begins
- Could a lung cancer drug designed for one mutation work for another?
- Could chemo plus immunotherapy double the punch against tough lung cancers?
- Repairing lungs from within: stem cells harvested from Patients' own airways tested for scarring disease